Scarica l'app Stockscreener
15.51
6.74%
0.98
Dopo l'orario di chiusura:
15.51
Precedente Chiudi:
$14.53
Aprire:
$14.76
Volume 24 ore:
1.16M
Relative Volume:
1.39
Capitalizzazione di mercato:
$998.14M
Reddito:
-
Utile/perdita netta:
$-221.04M
Rapporto P/E:
-4.1758
EPS:
-3.7143
Flusso di cassa netto:
$-178.65M
1 W Prestazione:
+4.73%
1M Prestazione:
-30.54%
6M Prestazione:
+7.48%
1 anno Prestazione:
+169.74%
Intervallo 1D:
$14.59
$15.56
Intervallo di 1 settimana:
$14.20
$15.78
Portata 52W:
$5.68
$23.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Nome
Cullinan Therapeutics Inc
Settore
Industria
Telefono
617-410-4650
Indirizzo
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
15.51 | 953.09M | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Iniziato | Citigroup | Buy |
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-08-21 | Ripresa | H.C. Wainwright | Buy |
| 2025-06-11 | Ripresa | Stifel | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-05-01 | Iniziato | Stifel | Buy |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-06-15 | Iniziato | TD Cowen | Outperform |
| 2022-11-21 | Iniziato | BTIG Research | Buy |
| 2021-04-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Iniziato | Evercore ISI | Outperform |
| 2021-02-02 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Iniziato | SVB Leerink | Outperform |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Reaffirmed as "Buy" by BTIG Research - MarketBeat
Cullinan Therapeutics' stock pullback offers a ... - Pluang
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases - Seeking Alpha
HC Wainwright Has Negative Forecast for CGEM Q1 Earnings - MarketBeat
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049 - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - uk.finance.yahoo.com
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $35 - Moomoo
510,325 Shares in Cullinan Therapeutics, Inc. $CGEM Purchased by Bank of America Corp DE - MarketBeat
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026 - Yahoo Finance
Cullinan Therapeutics - The Pharma Letter
CGEM Maintained by HC Wainwright & Co. -- Price Target Raised to $35 - GuruFocus
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $33 to $40 - Moomoo
CGEM Reiterated by BTIG -- Price Target Maintained at $40 - GuruFocus
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio - Investing News Network
Cullinan Therapeutics at stifel 2026 forum: autoimmune pipeline advances By Investing.com - Investing.com Canada
CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger - Stocktwits
Cullinan Therapeutics (CGEM) Eyes Key Autoimmune and AML Data Re - GuruFocus
Cullinan delays early-stage data for arthritis drug (CGEX) - Seeking Alpha
Cullinan Therapeutics (CGEM) Shares Drop 7% as CLN-978 Data Rele - GuruFocus
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs - Yahoo Finance
Cullinan Therapeutics (CGEM) Sets Q4 2026 Clinical Updates Amid High Price-to-Sales Valuation - GuruFocus
Cullinan Therapeutics Highlights Fourth Quarter 2026 - GlobeNewswire
Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data - Yahoo Finance
Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release – Has The Bull Case Changed? - Yahoo Finance
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 7.1%Here's What Happened - MarketBeat
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - Investing News Network
Phase III results could broaden opportunity for Cullinan’s lead cancer drug - The Pharma Letter
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Potential Upside of Over 57% Ignites Investor Interest - DirectorsTalk Interviews
Should Phase 3 Lung Cancer Data Require Action From Cullinan Therapeutics (CGEM) Investors? - simplywall.st
Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity? - Insider Monkey
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $42 - Moomoo
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $42 - Moomoo
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst CallSlideshow (NASDAQ:CGEM) 2026-09-14 - Seeking Alpha
Cullinan Oncology stock rating reaffirmed at Buy by TD Cowen - Investing.com South Africa
BTIG raises Cullinan Oncology stock price target on trial data - Investing.com
BTIG raises Cullinan Oncology stock price target on trial data By Investing.com - Investing.com Canada
Cullinan Therapeutics: The Market Shrugged At REZILIENT3, But Catalysts Await (CGEM) - Seeking Alpha
Stifel reiterates Cullinan Oncology stock Buy rating on trial data By Investing.com - Investing.com South Africa
Stifel reiterates Cullinan Oncology stock Buy rating on trial data - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap DownTime to Sell? - MarketBeat
Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results - Yahoo Finance
Cullinan Therapeutics Inc Azioni (CGEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cullinan Therapeutics Inc Azioni (CGEM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer |
Sep 08 '26 |
Sale |
21.57 |
8,000 |
172,560 |
158,844 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):